Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22774423 | 1.00 | DUT (0.34) | DUTKDM4ESMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL2880215 | 0.93 | DUT (0.35) | DUTKDM4EALDH1A1 | |
| SCHEMBL23067161 | 0.86 | DUT (0.31) | DUT | |
| SCHEMBL3756533 | 0.83 | DUT (0.35) | DUT | |
| SCHEMBL14680142 | 0.83 | L3MBTL1 (0.36) | DUT | |
| SCHEMBL29549857 | 0.83 | L3MBTL1 (0.36) | DUT | |
| SCHEMBL20660409 | 0.81 | DRD2 (0.32) | — | |
| SCHEMBL17555693 | 0.81 | DUT (0.37) | DUTKDM4EALDH1A1 | |
| SCHEMBL3752953 | 0.81 | DUT (0.34) | DUT | |
| SCHEMBL25183720 | 0.78 | KDM4E (0.30) | KDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097775-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| EP-2552923-B1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R & D IRELAND (IE) | 2014-03-26 | — | — | EP | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
| EP-2552923-A1 | MACROCYCLIC INTEGRASE INHIBITORS | Janssen R&D Ireland (IE) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011121105-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TYMP, PIM1, TYMS | DUT 58/4885KDM4E 911/4885SMN1; SMN2 2688/4885 |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | DUT 1413/4885KDM4E 2112/4885SMN1; SMN2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.